


# Drug—Drug Interactions



edited by  
A. David Rodrigues

# Drug—Drug Interactions

edited by

A. David Rodrigues

*Merck Research Laboratories  
West Point, Pennsylvania*



MARCEL DEKKER, INC.

NEW YORK • BASEL

**ISBN: 0-8247-0283-2**

This book is printed on acid-free paper.

**Headquarters**

Marcel Dekker, Inc.  
270 Madison Avenue, New York, NY 10016  
tel: 212-696-9000; fax: 212-685-4540

**Eastern Hemisphere Distribution**

Marcel Dekker AG  
Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland  
tel: 41-61-261-8482; fax: 41-61-261-8896

**World Wide Web**

<http://www.dekker.com>

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above.

**Copyright © 2002 by Marcel Dekker, Inc. All Rights Reserved.**

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

**PRINTED IN THE UNITED STATES OF AMERICA**

# **Drug—Drug Interactions**

# DRUGS AND THE PHARMACEUTICAL SCIENCES

## Executive Editor

**James Swarbrick**

*AAI, Inc.*

*Wilmington, North Carolina*

## Advisory Board

Larry L. Augsburger University of Maryland Baltimore, Maryland	David E. Nichols Purdue University West Lafayette, Indiana
--	--

Douwe D. Breimer Gorlaeus Laboratories Leiden, The Netherlands	Stephen G. Schulman University of Florida Gainesville, Florida
--	--

Trevor M. Jones The Association of the British Pharmaceutical Industry London, United Kingdom	Jerome P. Skelly Alexandria, Virginia
--	--

Hans E. Junginger Leiden/Amsterdam Center for Drug Research Leiden, The Netherlands	Felix Theeuwes Alza Corporation Palo Alto, California
--	---

Vincent H. L. Lee University of Southern California Los Angeles, California	Geoffrey T. Tucker University of Sheffield Royal Hallamshire Hospital Sheffield, United Kingdom
---	--

Peter G. Welling  
Institut de Recherche Jouveinal  
Fresnes, France

## DRUGS AND THE PHARMACEUTICAL SCIENCES

A Series of Textbooks and Monographs

1. Pharmacokinetics, *Milo Gibaldi and Donald Perrier*
2. Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control, *Sidney H. Willig, Murray M. Tuckerman, and William S. Hitchings IV*
3. Microencapsulation, *edited by J. R. Nixon*
4. Drug Metabolism: Chemical and Biochemical Aspects, *Bernard Testa and Peter Jenner*
5. New Drugs: Discovery and Development, *edited by Alan A. Rubin*
6. Sustained and Controlled Release Drug Delivery Systems, *edited by Joseph R. Robinson*
7. Modern Pharmaceuticals, *edited by Gilbert S. Banker and Christopher T. Rhodes*
8. Prescription Drugs in Short Supply: Case Histories, *Michael A. Schwartz*
9. Activated Charcoal: Antidotal and Other Medical Uses, *David O. Cooney*
10. Concepts in Drug Metabolism (in two parts), *edited by Peter Jenner and Bernard Testa*
11. Pharmaceutical Analysis: Modern Methods (in two parts), *edited by James W. Munson*
12. Techniques of Solubilization of Drugs, *edited by Samuel H. Yalkowsky*
13. Orphan Drugs, *edited by Fred E. Karch*
14. Novel Drug Delivery Systems: Fundamentals, Developmental Concepts, Biomedical Assessments, *Yie W. Chien*
15. Pharmacokinetics: Second Edition, Revised and Expanded, *Milo Gibaldi and Donald Perrier*
16. Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control, Second Edition, Revised and Expanded, *Sidney H. Willig, Murray M. Tuckerman, and William S. Hitchings IV*
17. Formulation of Veterinary Dosage Forms, *edited by Jack Blodinger*
18. Dermatological Formulations: Percutaneous Absorption, *Brian W. Barry*
19. The Clinical Research Process in the Pharmaceutical Industry, *edited by Gary M. Matoren*
20. Microencapsulation and Related Drug Processes, *Patrick B. Deasy*
21. Drugs and Nutrients: The Interactive Effects, *edited by Daphne A. Roe and T. Colin Campbell*
22. Biotechnology of Industrial Antibiotics, *Erick J. Vandamme*

23. *Pharmaceutical Process Validation*, edited by *Bernard T. Loftus and Robert A. Nash*
24. *Anticancer and Interferon Agents: Synthesis and Properties*, edited by *Raphael M. Ottenbrite and George B. Butler*
25. *Pharmaceutical Statistics: Practical and Clinical Applications*, *Sanford Bolton*
26. *Drug Dynamics for Analytical, Clinical, and Biological Chemists*, *Benjamin J. Gudzinowicz, Burrows T. Younkin, Jr., and Michael J. Gudzinowicz*
27. *Modern Analysis of Antibiotics*, edited by *Adjoran Aszalos*
28. *Solubility and Related Properties*, *Kenneth C. James*
29. *Controlled Drug Delivery: Fundamentals and Applications*, Second Edition, Revised and Expanded, edited by *Joseph R. Robinson and Vincent H. Lee*
30. *New Drug Approval Process: Clinical and Regulatory Management*, edited by *Richard A. Guarino*
31. *Transdermal Controlled Systemic Medications*, edited by *Yie W. Chien*
32. *Drug Delivery Devices: Fundamentals and Applications*, edited by *Praveen Tyle*
33. *Pharmacokinetics: Regulatory • Industrial • Academic Perspectives*, edited by *Peter G. Welling and Francis L. S. Tse*
34. *Clinical Drug Trials and Tribulations*, edited by *Allen E. Cato*
35. *Transdermal Drug Delivery: Developmental Issues and Research Initiatives*, edited by *Jonathan Hadgraft and Richard H. Guy*
36. *Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms*, edited by *James W. McGinity*
37. *Pharmaceutical Pelletization Technology*, edited by *Isaac Ghebresellassie*
38. *Good Laboratory Practice Regulations*, edited by *Allen F. Hirsch*
39. *Nasal Systemic Drug Delivery*, *Yie W. Chien, Kenneth S. E. Su, and Shyi-Feu Chang*
40. *Modern Pharmaceutics: Second Edition, Revised and Expanded*, edited by *Gilbert S. Banker and Christopher T. Rhodes*
41. *Specialized Drug Delivery Systems: Manufacturing and Production Technology*, edited by *Praveen Tyle*
42. *Topical Drug Delivery Formulations*, edited by *David W. Osborne and Anton H. Amann*
43. *Drug Stability: Principles and Practices*, *Jens T. Carstensen*
44. *Pharmaceutical Statistics: Practical and Clinical Applications*, Second Edition, Revised and Expanded, *Sanford Bolton*
45. *Biodegradable Polymers as Drug Delivery Systems*, edited by *Mark Chasin and Robert Langer*
46. *Preclinical Drug Disposition: A Laboratory Handbook*, *Francis L. S. Tse and James J. Jaffe*
47. *HPLC in the Pharmaceutical Industry*, edited by *Godwin W. Fong and Stanley K. Lam*
48. *Pharmaceutical Bioequivalence*, edited by *Peter G. Welling, Francis L. S. Tse, and Shrikant V. Dinghe*

49. Pharmaceutical Dissolution Testing, *Umesh V. Banakar*
50. Novel Drug Delivery Systems: Second Edition, Revised and Expanded, *Yie W. Chien*
51. Managing the Clinical Drug Development Process, *David M. Cocchetto and Ronald V. Nardi*
52. Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control, Third Edition, *edited by Sidney H. Willig and James R. Stoker*
53. Prodrugs: Topical and Ocular Drug Delivery, *edited by Kenneth B. Sloan*
54. Pharmaceutical Inhalation Aerosol Technology, *edited by Anthony J. Hickey*
55. Radiopharmaceuticals: Chemistry and Pharmacology, *edited by Adrian D. Nunn*
56. New Drug Approval Process: Second Edition, Revised and Expanded, *edited by Richard A. Guarino*
57. Pharmaceutical Process Validation: Second Edition, Revised and Expanded, *edited by Ira R. Berry and Robert A. Nash*
58. Ophthalmic Drug Delivery Systems, *edited by Ashim K. Mitra*
59. Pharmaceutical Skin Penetration Enhancement, *edited by Kenneth A. Walters and Jonathan Hadgraft*
60. Colonic Drug Absorption and Metabolism, *edited by Peter R. Bieck*
61. Pharmaceutical Particulate Carriers: Therapeutic Applications, *edited by Alain Rolland*
62. Drug Permeation Enhancement: Theory and Applications, *edited by Dean S. Hsieh*
63. Glycopeptide Antibiotics, *edited by Ramakrishnan Nagarajan*
64. Achieving Sterility in Medical and Pharmaceutical Products, *Nigel A. Halls*
65. Multiparticulate Oral Drug Delivery, *edited by Isaac Ghebre-Sellassie*
66. Colloidal Drug Delivery Systems, *edited by Jörg Kreuter*
67. Pharmacokinetics: Regulatory • Industrial • Academic Perspectives, Second Edition, *edited by Peter G. Welling and Francis L. S. Tse*
68. Drug Stability: Principles and Practices, Second Edition, Revised and Expanded, *Jens T. Carstensen*
69. Good Laboratory Practice Regulations: Second Edition, Revised and Expanded, *edited by Sandy Weinberg*
70. Physical Characterization of Pharmaceutical Solids, *edited by Harry G. Brittain*
71. Pharmaceutical Powder Compaction Technology, *edited by Göran Alderborn and Christer Nyström*
72. Modern Pharmaceutics: Third Edition, Revised and Expanded, *edited by Gilbert S. Banker and Christopher T. Rhodes*
73. Microencapsulation: Methods and Industrial Applications, *edited by Simon Benita*
74. Oral Mucosal Drug Delivery, *edited by Michael J. Rathbone*
75. Clinical Research in Pharmaceutical Development, *edited by Barry Bleidt and Michael Montagne*



76. *The Drug Development Process: Increasing Efficiency and Cost Effectiveness*, edited by Peter G. Welling, Louis Lasagna, and Umesh V. Banakar
77. *Microparticulate Systems for the Delivery of Proteins and Vaccines*, edited by Smadar Cohen and Howard Bernstein
78. *Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control*, Fourth Edition, Revised and Expanded, Sidney H. Willig and James R. Stoker
79. *Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms: Second Edition, Revised and Expanded*, edited by James W. McGinity
80. *Pharmaceutical Statistics: Practical and Clinical Applications*, Third Edition, Sanford Bolton
81. *Handbook of Pharmaceutical Granulation Technology*, edited by Dilip M. Parikh
82. *Biotechnology of Antibiotics: Second Edition, Revised and Expanded*, edited by William R. Strohl
83. *Mechanisms of Transdermal Drug Delivery*, edited by Russell O. Potts and Richard H. Guy
84. *Pharmaceutical Enzymes*, edited by Albert Lauwers and Simon Scharpé
85. *Development of Biopharmaceutical Parenteral Dosage Forms*, edited by John A. Bontempo
86. *Pharmaceutical Project Management*, edited by Tony Kennedy
87. *Drug Products for Clinical Trials: An International Guide to Formulation • Production • Quality Control*, edited by Donald C. Monkhouse and Christopher T. Rhodes
88. *Development and Formulation of Veterinary Dosage Forms: Second Edition, Revised and Expanded*, edited by Gregory E. Hardee and J. Desmond Baggot
89. *Receptor-Based Drug Design*, edited by Paul Leff
90. *Automation and Validation of Information in Pharmaceutical Processing*, edited by Joseph F. deSpautz
91. *Dermal Absorption and Toxicity Assessment*, edited by Michael S. Roberts and Kenneth A. Walters
92. *Pharmaceutical Experimental Design*, Gareth A. Lewis, Didier Mathieu, and Roger Phan-Tan-Luu
93. *Preparing for FDA Pre-Approval Inspections*, edited by Martin D. Hynes III
94. *Pharmaceutical Excipients: Characterization by IR, Raman, and NMR Spectroscopy*, David E. Bugay and W. Paul Findlay
95. *Polymorphism in Pharmaceutical Solids*, edited by Harry G. Brittain
96. *Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products*, edited by Louis Rey and Joan C. May
97. *Percutaneous Absorption: Drugs–Cosmetics–Mechanisms–Methodology*, Third Edition, Revised and Expanded, edited by Robert L. Bronaugh and Howard I. Maibach

98. Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development, *edited by Edith Mathiowitz, Donald E. Chickering III, and Claus-Michael Lehr*
99. Protein Formulation and Delivery, *edited by Eugene J. McNally*
100. New Drug Approval Process: Third Edition, The Global Challenge, *edited by Richard A. Guarino*
101. Peptide and Protein Drug Analysis, *edited by Ronald E. Reid*
102. Transport Processes in Pharmaceutical Systems, *edited by Gordon L. Amidon, Ping I. Lee, and Elizabeth M. Topp*
103. Excipient Toxicity and Safety, *edited by Myra L. Weiner and Lois A. Kotkoskie*
104. The Clinical Audit in Pharmaceutical Development, *edited by Michael R. Hamrell*
105. Pharmaceutical Emulsions and Suspensions, *edited by Francoise Nielloud and Gilberte Marti-Mestres*
106. Oral Drug Absorption: Prediction and Assessment, *edited by Jennifer B. Dressman and Hans Lennemäs*
107. Drug Stability: Principles and Practices, Third Edition, Revised and Expanded, *edited by Jens T. Carstensen and C. T. Rhodes*
108. Containment in the Pharmaceutical Industry, *edited by James P. Wood*
109. Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control from Manufacturer to Consumer, Fifth Edition, Revised and Expanded, *Sidney H. Willig*
110. Advanced Pharmaceutical Solids, *Jens T. Carstensen*
111. Endotoxins: Pyrogens, LAL Testing, and Depyrogenation, Second Edition, Revised and Expanded, *Kevin L. Williams*
112. Pharmaceutical Process Engineering, *Anthony J. Hickey and David Ganderton*
113. Pharmacogenomics, *edited by Werner Kalow, Urs A. Meyer, and Rachel F. Tyndale*
114. Handbook of Drug Screening, *edited by Ramakrishna Seethala and Prabhavathi B. Fernandes*
115. Drug Targeting Technology: Physical • Chemical • Biological Methods, *edited by Hans Schreier*
116. Drug-Drug Interactions, *edited by A. David Rodrigues*
117. Pharmaceutical Process Scale-Up, *edited by Michael Levin*

#### ADDITIONAL VOLUMES IN PREPARATION

Handbook of Pharmaceutical Analysis, *edited by Lena Ohannesian and Anthony J. Streeter*

Modern Pharmaceutics: Fourth Edition, Revised and Expanded, *edited by Gilbert S. Banker and Christopher T. Rhodes*

Dermatological and Transdermal Formulations, *edited by Kenneth A. Walters*

## Preface

Our knowledge of the various human drug metabolizing enzyme systems continues to grow. In recent years, this expansion in knowledge has been fueled by significant advances in molecular biology, the increased availability of human tissue, and the development of reliable model systems and sensitive assay methods for studying drug metabolism *in vitro*. In fact, *in vitro* methodology has become increasingly “standardized” and has been widely accepted by academic institutions, the pharmaceutical industry and regulatory agencies. However, while *in vitro* approaches can be used to screen large numbers of compounds preclinically, it is recognized that accurate forecasting of drug–drug interaction is predicated on sound knowledge of *in vivo* pharmacokinetics and the availability of validated *in vitro*–*in vivo* correlations.

Towards this end, the purpose of *Drug–Drug Interactions* is to relate pharmacokinetic concepts to the Michaelis–Menten kinetics describing *in vitro* enzyme-catalyzed biotransformation reactions. With kinetics as a foundation, the topic of drug–drug interactions is presented in terms of the various *in vitro* models, representative enzyme systems (e.g., cytochromes P450 and UDP-glucuronosyltransferases), and approaches (e.g., kinetics-based *in vitro*–*in vivo* correlations, computer-aided molecular modeling studies and informational databases). Although the subject matter focuses on metabolism-based drug–drug interactions resulting from inhibition and induction of drug-metabolizing enzymes, it is acknowledged that drug–drug interactions can occur via other mechanisms (e.g., competition for drug transporters and binding sites on plasma proteins, or pharmacodynamic drug–drug interactions).

An additional objective of this book is to present the subject of drug–drug interactions from preclinical, clinical, toxicological, regulatory, and marketing

perspectives. Therefore, it is hoped that *Drug-Drug Interactions* will be useful to students and seasoned scientists in the fields of molecular biology, pharmacokinetics, enzymology, toxicology, drug metabolism, pharmacology, clinical pharmacology, medicine, and medicinal chemistry. The subject matter will also appeal to those involved in the marketing of drugs. In the end, the book will have achieved its purpose if it serves merely to provoke constructive debate among individuals within these various disciplines.

A. David Rodrigues

## Contributors

**Thomas E. Bougan** Applied Technical Systems, Bremerton, Washington

**L. Alayne Burton** XenoTech, LLC, Kansas City, Kansas

**Sonia P. Carlson** Department of Pharmaceutics, University of Washington, Seattle, Washington

**Stephen E. Clarke** Department of Drug Metabolism and Pharmacokinetics, Glaxo SmithKline Pharmaceuticals, Ware, United Kingdom

**Marcel J. de Groot** Molecular Informatics, Structure and Design, Pfizer Global Research & Development, Kent, United Kingdom

**Liang-Shang Gan** Department of Drug Metabolism and Pharmacokinetics, DuPont Pharmaceuticals Company, Newark, Delaware

**David J. Greenblatt** Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, and Division of Clinical Pharmacology, New England Medical Center, Boston, Massachusetts

**Stephen D. Hall** Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana

**Peter Honig** Office of Postmarketing and Drug Risk Assessment, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland

**Shiew-Mei Huang** Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland

**Barry C. Jones** Pfizer Global Research & Development, Kent, United Kingdom

**David R. Jones** Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana

**Kenneth R. Korzekwa** Camitro Corporation, Menlo Park, California

**Hiroyuki Kusuhara** Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, University of Tokyo and CREST, Japan Science and Technology Corporation, Tokyo, Japan

**Lawrence J. Lesko** Office of Clinical Pharmacology and Biopharmaceutics, U.S. Food and Drug Administration, Rockville, Maryland

**René H. Levy** Department of Pharmaceutics and Department of Neurological Surgery, University of Washington, Seattle, Washington

**Jiunn H. Lin** Drug Metabolism, Merck & Company, West Point, Pennsylvania

**Gang Luo** Department of Drug Metabolism and Pharmacokinetics, DuPont Pharmaceuticals Company, Newark, Delaware

**Ajay Madan** XenoTech, LLC, Kansas City, Kansas

**Sidney D. Nelson** Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington

**Deborah A. Nicoll-Griffith** Department of Molecular Biology, Merck Frosst Canada, Quebec, Canada

**Brian W. Ogilvie** XenoTech, LLC, Kansas City, Kansas

**Andrew Parkinson** XenoTech, LLC, Kansas City, Kansas

**Paul G. Pearson** Drug Metabolism, Merck & Company, West Point, Pennsylvania

**Kevin J. Petty** Clinical Pharmacology, Merck Research Laboratories, Blue Bell, Pennsylvania

**Isabelle Ragueneau-Majlessi** Department of Pharmaceutics, University of Washington, Seattle, Washington

**Rory P. Remmel** Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota

**Malcolm Rowland** School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom

**Danny D. Shen** Department of Pharmaceutics, University of Washington, Seattle, Washington

**Jose M. Silva** Department of Molecular Biology, Merck Frosst Canada, Quebec, Canada

**Yuichi Sugiyama** Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, University of Tokyo and CREST, Japan Science and Technology Corporation, Tokyo, Japan

**Robert Temple** Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland

**Anton M. ter Laak** Department of Pharmacochemistry, Vrije Universiteit, Amsterdam, The Netherlands

**Dhiren R. Thakker** Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina

**Kenneth E. Thummel** Department of Pharmaceutics, University of Washington, Seattle, Washington

**Matthew D. Troutman** Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina

**Etsuko Usuki** XenoTech, LLC, Kansas City, Kansas

**José M. Vega** Clinical Pharmacology, Merck Research Laboratories, Blue Bell, Pennsylvania

**Nico P. E. Vermeulen** Section of Molecular Toxicology, Department of Pharmacology, Vrije Universiteit, Amsterdam, The Netherlands

**Lisa L. von Moltke** Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, and Division of Clinical Pharmacology, New England Medical Center, Boston, Massachusetts

**Grant R. Wilkinson** Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee

**Roger Williams** U.S. Pharmacopeia, Rockville, Maryland



## Useful Information

### WEBSITES

<http://www.dml.georgetown.edu/depts/pharmacology/p450ref2.html>

<http://www.accp.com/p450.html>

<http://www.fda.gov/cder/guidance/index.htm>

<http://www.gentest.com>

<http://www.panvera.com>

<http://www.pharmacy.org/wwwdbs.html>

<http://www.druginfonet.com/faq/faqintac.htm>

<http://cponline.gsm.com/sample/interact/sample7.htm>

[http://www.jag.on.ca/asp\\_bin/Drug%20interactions.asp](http://www.jag.on.ca/asp_bin/Drug%20interactions.asp)

<http://www.unmc.edu/library/pharm/adr.html>

[http://www.ndmainfo.org/consumerInfo/04\\_02\\_03.html](http://www.ndmainfo.org/consumerInfo/04_02_03.html)

<http://dmd.aspetjournals.org/>

<http://jpet.aspetjournals.org/>

<http://www.xenotechllc.com>

<http://base.icgeb.trieste.it/p450/>

<http://www.invitrotech.com>

<http://216.70.174.79/transporter/>

### BOOKS

GL Amidon. Mechanisms of Drug Interactions. New York: Springer, 1996.

DA Ciraulo. Drug Interactions in Psychiatry. Baltimore: Williams and Wilkins, 1995.